Five Prime Therapeutics (FPRX) Misses Q2 EPS by 1c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q2 EPS of ($0.45), $0.01 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.92 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c